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Abstract. Analyses of the population genetic structure of schistosomes under the “Schistosomiasis Consortium for
Operational Research and Evaluation” (SCORE) contrasting treatment pressure scenarios in Tanzania, Niger, and Zan-
zibar were performed to provide supplementary critical information withwhich to evaluate the impact of these large-scale
control activities and guide how activities could be adjusted.We predicted that population genetic analyses would reveal
information on a range of important parameters including, but not exclusive to, recruitment and transmission of geno-
types, occurrence of hybridization events, differences in reproductive mode, and degrees of inbreeding, and hence, the
evolutionary potential, and responses of parasite populations under contrasting treatment pressures. Key findings
revealed that naturally high levels of gene flow and mixing of the parasite populations between neighboring sites were
likely to dilute any effects imposedby theSCORE treatment arms. Furthermore, significant inherent differences in parasite
fecundity were observed, independent of current treatment arm, but potentially of major impact in terms of maintaining
high levels of ongoing transmission in persistent “biological hotspot” sites.Within Niger, naturally occurringSchistosoma
haematobium/Schistosoma bovis viable hybrids were found to be abundant, often occurring in significantly higher pro-
portions than that of single-species S. haematobium infections. By examining parasite population genetic structures
across hosts, treatment regimens, and the spatial landscape, our results to date illustrate key transmission processes
over and above that which could be achieved through standard parasitological monitoring of prevalence and intensity
alone, as well as adding to our understanding of Schistosoma spp. life history strategies in general.
INTRODUCTION
Schistosomiasis is a neglected tropical disease, caused by
dioecious blood flukes of the genus Schistosoma, estimated
to currently infect more than 220 million people.1 The disease
burden is greatest (at least 90%) within sub-Saharan Africa
(SSA), where the main species causing human schistosomi-
asis are Schistosoma mansoni (a causative agent of intestinal
schistosomiasis) andSchistosomahaematobium (andhybrids
therein, the causative agents of urogenital schistosomiasis),
transmitted via eggs excreted in feces or urine, respectively.
After 60 years of major multidisciplinary control efforts, great
success has been achieved against Schistosoma japonicum
(a causative agent of intestinal schistosomiasis) within China,
and actual elimination/interruption of transmission has been
achieved in Japan. However, although efforts to control
S. mansoni and S. haematobium through large-scale pre-
ventive chemotherapy (PC)/mass drug administration (MDA)
with praziquantel (PZQ) across SSA have also had a sub-
stantial impact on preventing or relieving morbidity,2 consid-
erable work is still needed to achieve elimination.
Contributing to this challenge, a recent work serves to
highlight that schistosomes are highly complex organisms,
and numerous essential characteristics of their biology and
epidemiology remain unknown. Many of these unknowns
potentially pose major challenges for sustainable disease
control and certainly for the interruption of transmission. For
instance, with more sensitive diagnostic surveillance tools,
there are reports that prevalence levels are substantially
greater thanpreviously thought,3 especially amongpreschool-
aged children and infants.4 There is also evidence of main-
tenance and reemergence of schistosomiasis in previously
controlled regions, exacerbated, at least in part, through
wildlife and/or domestic animal reservoirs, not only in Asia5–7
but also it is becoming increasingly apparent within Africa
too.8,9 Linked to this, it is also now known that hybrid/
introgressed Schistosoma species are common across
several high-endemicity regions of SSA,10 especially West
Africa,11–13 and have recently spread into Europe.14 Perhaps,
most disconcerting of all in terms of achieving the World
Health Organization (WHO) goals of sustainable control,
elimination of schistosomiasis as a public health problem,
and ultimately interruption of transmission is the potential of
reduced drug efficacy among populations under high chemo-
therapeutic pressure.15 Yet accurate interpretation of preva-
lence and intensity data is often hampered because of the poor
sensitivity of traditional parasitological diagnostics, particularly
at low intensities of infection.16 Finally, there remain many
critical unresolvedquestionson the schistosomes’ resilience to
the various interventions imposed on them.
The “Schistosomiasis Consortium for Operational Re-
search and Evaluation” (SCORE; https://score.uga.edu/) was
designed to conduct large-scale operational health research
into morbidity control and elimination.17–19 The overall aim
within the SCORE gaining and sustaining control studies was
to evaluate different schedules for providing PC throughMDA
either delivered through community-wide treatment (CWT) or
through school-based treatment (SBT) (Figure 1A and B).
Analyses of the population genetic structure of schisto-
somes under these contrasting scenarioswere proposed to
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contribute supplementary critical information with which to
evaluate the impact of large-scale control activities and ideally
guide how activities could be adjusted. In particular, it was
predicted that population genetic analyses should reveal
novel informationoneffective parasite population size andany
bottlenecks imposed, the role of refugia, recruitment and/or
ongoing transmission of genotypes, occurrence of hybrid-
ization events, differences in reproductivemode, and degrees
of inbreeding, as well as fitness traits of individual parasites
that may be evidenced through sibship analyses, impact of
drug holidays (predicting differential bounce back under dif-
ferent times), and, hence, overall, the evolutionary potential of
parasite populations under contrasting drug pressures. Fur-
thermore, it was predicted that applying population genetic
analyses to such parasite populations under contrasting
treatment pressures should add to our understanding of their
life history strategies and to the importance of ecological and
evolutionary theory in general.
The initial SCORE population genetic subcomponents fo-
cusedon villages in the gaining control studieswhere baseline
infection prevalence levels were at least 25%, and specifi-
cally those two of the six intervention arms with the most
contrasting schedules of PZQ pressure: CWT every year
versus SBT every other year. This design was followed
throughout forS.mansoni in Tanzania, with samples collected
from school-aged children (age [predominantly] 9–12 years)
before MDA from areas with intestinal schistosomiasis (but
low or zero co-endemic urogenital schistosomiasis) close to
Lake Victoria (Figure 1A). In Niger, initial sampling focused on
school-aged children (age 9–12 years) from the Kolla and Say
districts of the Niger River valley, regions of high urogenital
endemicity (but little or zero co-endemic intestinal schisto-
somiasis). However, midway through the study, because of
issues of randomization within the main Niger SCORE pro-
gram, the study design was changed to evaluate biannual
treatment to annual treatment (CWT × 2 versus CWT × 1,
SBT × 2 versus SBT × 1; Figure 1B). In addition, from 2011,
population genetics studies were also included as a compo-
nent of the SCORE elimination study within the “Zanzibar
Elimination of Schistosomiasis Transmission” (ZEST) alliance.
Zanzibar is composed of an archipelago including the two
main islands, Unguja and Pemba, located approximately
35–60 km off mainland Tanzania. The relative isolation of
these island populations makes them particularly suitable for
FIGURE 1. Schistosomiasis Consortium for Operational Research and Evaluation treatment program designs incorporating population genetic
analyses encompassing: (A) school-based vs. community-based mass drug administration (MDA) Schistosoma mansoni control in Tanzania, (B)
biannual vs. annual MDA across school-based and community-basedSchistosoma haematobium control in Niger, and (C) biannual MDA alone vs.
biannual MDA + snail control vs. biannual MDA + behavioral change elimination interventions on S. haematobium in Zanzibar.
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assessing disease control strategies, complemented by an
apparent lack of potential animal host reservoirs/zoonotic
schistosomiasis transmission (but see ref. 20) and an
S. haematobium population genetic lineage distinct from that
of much of mainland Africa.21 The overreaching aim of ZEST
was to evaluate the ability of contrasting intervention strate-
gies to achieve elimination as a public health problem on
Pemba and complete interruption of transmission on Unguja
within 5 years.18,22–24 The cluster randomized trial involved
three study arms, implemented across 45 randomly selected
shehias (small administrative regions) on each island, to as-
sess the differential impact of the following: 1) biannual MDA
alone, 2) biannual MDA + snail control, and 3) biannual MDA +
behavioral interventions (Figure 1C).
Here,wesummarize anddiscusssomeof the keyfindings to
date from these studies and how they contribute to our un-
derstanding of the population genetics of schistosomes in
response to differential control selection pressures. We also
identify some of the main continuing challenges and discuss
how they relate to the interpretation of standard monitoring
and evaluation data, as well as the feasibility of achieving the
disease control targets.
The need for new tools to answer more complex
questions. The two most commonly used indicators to de-
termine the impact of schistosome control programs are
prevalence and intensity of infection (typically measured as
eggs per gram [EPG] of feces for intestinal schistosomes and
eggs per 10mL of urine for urogenital infections). Intensities of
infection are assumed to relate indirectly to the degree of host
morbidity and directly to the hosts’ potential contributions to
transmission. Prevalence and intensity data can also be used
to evaluate the efficacy of treatment through the cure rate and
the egg reduction rate (ERR), the latter recommended by the
WHO.25 Cure rate is a measure of the percentage of individ-
uals that no longer excrete eggs after treatment compared
with baseline, whereas the ERR measures the percentage
reduction in the number of eggs passed.26 Both of these
measurements are subject to the sensitivity and specificity of
the assay used. Reduced or suboptimal drug efficacy in a
population is flagged when the observed ERR is less than the
reference/expected value by at least 10%.25 Only recently
have statistical methods been implemented to estimate and
understand variability in drug efficacy among individuals, in-
cluding identification of individual and trial design factors as-
sociated with treatment response.27 Efforts are underway to
collate, standardize, and analyze, on a global scale, individual
data on responses to antischistosomal treatment, with goals
that include the optimization of treatment regimens, the de-
velopment of enhanced efficacy monitoring strategies, and,
ultimately, new approaches to mitigate the risk of emerging
FIGURE 1. Continued.
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drug resistance.28 However, even with improved statistical
tools, and the burgeoning use of mathematical transmission
models to predict the impact of intervention strategies and
inform appropriate, achievable control, and elimination
goals,29,30 empirical information on the impact of MDA on
parasite populations remains fundamentally limited by the
reliance on these indirect measures of infection, that is, egg
counts. For schistosomes, this is further exacerbated asdirect
quantification, and/or molecular characterization, of adult
worm burden from within humans is not feasible because of
the inaccessibility of adult worms within their intravascular
locations (unlike that formany of the soil-transmitted intestinal
helminths, which can be obtained by chemoexpulsion). This
raises fundamental and unresolved questions on the pop-
ulation biology of schistosomes that could play a key role in
shaping the transmission dynamics of the parasite and its
potential response or resilience to the treatment.31,32
In the past, population genetic analyses of schistosomes
relied on the infection of laboratory-reared snails to obtain
cercariae, infecting laboratory-reared rodents and then
obtaining the passaged adult worms by perfusions. However,
with the development of novel methodologies for sample
storage of single miracidia and cercariae stages collected
directly from natural human and snail infections, respectively,
on Whatman FTA cards (GE Healthcare Life Sciences, Buck-
inghamshire, United Kingdom), these logistical, ethical, and
biological caveats have been circumvented.33,34 Additional
refinements developed through SCORE studies and beyond
now allow repeat analyses on unamplified genomic DNA,
cost-effectively and without genome amplification bias,
thereby improving data quality and giving the potential for
greater analytical depth.35,36 Such new methodologies and
refinements allow an enormous reduction in the logistical ef-
fort required in assaying parasite populations. Furthermore,
these methodologies can be applied to natural schistosome
populations across continents, allowing wide-scale genetic
and genomic analyses of schistosome populations over
space and time, and encompasses all life stages from adult
worms to free-livingmiracidia and cercariae (e.g., refs. 37–39).
Microsatellites remain one of the most powerful Mendelian
markers currently available, although the mutation rate varies
across loci, and are ideal for population genetic studies to
identify clusters of genetically related individuals. This is po-
tentially indicative of population-level differences over space
and time, as well as bottleneck effects, and of both histor-
ical and contemporary population-level changes. A number
of Schistosoma species–specific microsatellite markers
have thus been developed and evaluated—from those for
S. japonicum in Asia5,6 to S. mansoni40–42 and, more recently,
S. haematobium.40,43,44 For theSCORETanzanianS.mansoni
samples, two multiplex microsatellite assays were developed
from 17 previously published microsatellite loci, which span-
ned theS.mansoni genome.40–42 Following data cleaning and
quality assessment, 13 of the 17 microsatellites loci were
FIGURE 1. Continued.
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successfully amplified. Similarly, for the SCORE samples
from Niger and Zanzibar, we developed two novel multi-
plex microsatellite assays to enable cost-effective simul-
taneous amplification of 18 informative microsatellite loci
of S. haematobium populations.39,45 However, the cross-
reactivity of these S. haematobium microsatellite loci with
other medically and veterinary important schistosomes
across the closely related S. haematobium group species re-
quired additional consideration, particularly given the ability of
species within this group to hybridize.12 The advances in the
DNA preparation of schistosome larval stages stored on
Whatman FTA cards further enabled both the replication
within technique and also the use of additional tools and
techniques to be performed on the same individual Schisto-
soma larval samples. In particular, we were thus able to in-
clude species diagnostic PCR’s andDNAsequencing through
analysis of mitochondrial cox1 and nuclear ITS regions on the
Nigerian samples.11
Key findings to date from the SCORE population ge-
netics studies. Key results to date of the SCORE population
genetic datasets indicate that, within the Tanzanian studies,
there was little or no differential impact of annual CWT or SBT
on the population genetic structure of S. mansoni, with no
significant clustering or genetic differentiation by treatment or
by year. Instead, it appeared that a large refugia of parasites
from untreated individuals in the community and/or in neigh-
boringcommunities undergoingdifferent treatment schedules
allowed for high levels of gene flow and, hence, a mixing of
the parasite population between years and between sites.
Any observed genetic differentiation at the village or school
level appeared most likely to be explicable by the eco-
epidemiological location itself (such as distance to water or
human population movement), rather than the SCORE treat-
ment arm. This is consistent with the previous work that ob-
served that most of the genetic diversity in S. mansoni occurs
at the human host level, rather than at the village or district
level.44,46,47 Infrapopulation genetic diversity is usually inter-
preted as the combined outcome of the genetic diversity of
parasites circulating in the environment, differences in expo-
sure due to variability in host behaviors, particularly those
related to water contact; that is, location, duration, and time of
day, as well as parasite establishment, often dependent on
host gender and immune response. These factors could well
be predicted to dilute any effect imposed by the SCORE-
contrasting treatment arms, particularly under conditions of
the high gene flow that was apparent across these lacustrine
Tanzanian populations.
Within the SCORE Niger data sets, there were also no sig-
nificant differences observed between the original SBT and
CWT in termsof genetic diversity and/or bottlenecking effects.
However, although there appeared to be no significant clus-
tering or genetic differentiation by CWT × 1 and CWT × 2
treatment arms, the greatest reduction in overall genetic di-
versity levels was observed by the end of the study between
the SBT × 2 relative to SBT × 1, potentially consistent with the
greater drug pressures (SBT × 2) imposed on these groups.
Furthermore, an extensive proportion of hybrid schistosomes,
rather than S. haematobium, within many of the Niger sites
was apparent.
In the SCORE Zanzibar elimination study within ZEST, the
greatest differences overall, both in terms of genetic sub-
structuring and parasite fecundity (see in the following text),
were observed between the islands, consistent with Pemba’s
higher mean infection intensities than Unguja.18 Population
genetic analyses also revealed a number of important issues
that could not have been detected by classical parasitological
prevalence and intensity measures alone. For instance, the
key outcome of the main SCORE study was that, although
MDA substantially reduced the S. haematobium prevalence
and infection intensity, and, hence, “elimination as a public
health problem,” it was insufficient to interrupt transmission
either alone or when combined with either snail control or
behavioral change activities.18,22 Yet, ongoing population
genetic analyses indicate the strongest selective pressures
placed on these S. haematobium populations, as suggested
by both genetic diversity and outbreeding estimates, together
with reductions in the estimated number of adult worms pre-
sent within each child/adult host, were observed in theMDA +
snail control arms. Furthermore, on each island, it appeared
thatmany of the shehiaswith the highest fecundity levelswent
on to become persistent hotspots (PHS) relative to those
where control was successful. These findings thus highlight
the additional contributions that population genetic analyses
can make in elucidating biological drivers, and potential
gene–environmental interactions, that can lead to areas
remaining PHS48,49 despite ongoing control measures.
However, even with such sensitive and specific population
genetic tools, interrogation of these SCORE datasets also
highlighted that many challenges remain for analyses and in-
terpretation. For instance, one of the original aims of SCORE
population genetic analyses was to examine the differential
impact of drug pressure on the potential for bottlenecking
events as well as effective population sizes (Ne) (or the ef-
fective number of breeders contributing to the next generation
[Nb]) of the remaining schistosomes. Analyses of both Ne/Nb
within both our SCORE S. haematobium datasets from Zan-
zibar and Niger (unpublished observations) using two avail-
able distinct software packages produced notably different
patterns, resulting in too much uncertainty to allow conclu-
sions to be drawn. It was evident that further tools and ana-
lytical development would be required for the Schistosoma
system to enable robust estimates of Ne/Nb. Indeed, a pre-
vious study that used parentage analysis to quantify family
structure (including Nb and the number of full-sib families)
showed that the reproductive success of breeding schisto-
somes was likely skewed, resulting in differential representa-
tion of each family in the offspring pool.32 It is thus likely that
different reproductive outputs could affect the results of sta-
tistical models used to estimate female worm burdens from
miracidial offspring data using parentage analysis.31 Similarly,
sibship reconstruction is a form of parentage analysis that can
be used to identify the number of helminth parental genotypes
infecting individual hosts using genetic data on only their
offspring. However, methods for inferring worm burdens from
sibship reconstruction data on numbers of unique parental
genotypes were lacking, limiting the method’s scope of ap-
plication. Therefore, to proceed with our SCORE population
genetic analyses, further statistical methods for estimating
female worm burdens from data on the unique number of
distinct female parental genotypes derived from sibship re-
construction were developed31 and applied to both the
S. haematobium and S. mansoni SCORE datasets to produce
more robustmeasureson thewithin-host parasite populations
present.
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The challenge of density dependence and differential
fecundity. Potential density dependence among schisto-
some populations raises a number of important public health
implications. Density dependencies can regulate parasite re-
production, govern their transmission dynamics, influence the
interpretation of standard parasitological egg count data
collected duringmonitoring and evaluation activities (because
using egg counts as a proxy for worm burden depends on the
relationship between these two stages in the parasite life-
cycle), and can enhance resilience to interventions. Density
dependence can be either positive (density-dependent facili-
tation) or negative (density-dependent inhibition). For exam-
ple, in dioecious organisms such as schistosomes, the
probability of a female worm encountering a male worm and
forming a mating pair may be so low at low parasite densities
that reproduction is restricted, whereas at higher parasite
densities, the probability of mating pair forming and suc-
cessful reproduction occurring increases—hence positive
density-dependent facilitation. By contrast, in negative
density-dependent inhibition, parasite population growth is
inhibited at higher parasite densities because of a reduction in
per capita egg contribution by each female worm (= adult
worm pair) as a function of within-host infection intensity
(Figure 2). Competition due to limited host resources such as
space and nutrients, as well as immunological host re-
sponses, are possible mechanisms driving this process.50,51
Whether and to what extent density-dependent processes
regulate the fecundity of schistosomes is an unresolved,
longstanding question because, as stated earlier, it is not
possible to directly quantify the relationship between Schis-
tosoma egg counts and worm burdens (at least within human
hosts). Furthermore, there appears to be no simple worm–
egg/larva relationship because of either the trapping of eggs in
host tissues and/or to the occurrence of density-dependent
mechanisms. The strongest direct evidence for density-
dependent fecundity inhibition in schistosomes was gener-
ated over 40 years ago, from two human autopsy studies
providing data on S. mansoni and S. haematobium worm
burdens and associated egg counts.52,53 However, further
statistical analyses of these datasets have provided contro-
versial andcontradictoryconclusions.54–56More recentstudies
have taken a different approach, by relatingS.mansoni in egg
counts to circulating anodic (CAA) and cathodic (CCA) anti-
gens, glycoconjugates secreted from the gut of schisto-
somes, and found the slopes less than unity, suggestive of
density dependence.57,58 Still, the existence of a direct re-
lationship between CAA or CCA antigens and worm burdens
has not been proven in humans because it is not possible to
exclude other mechanisms affecting antigen production and
clearance.58–60
One recent population genetic study, however, estimated
the number of adultwormgenotypes ofS.mansoni in Tanzanian
children using parentage analysis and sibship reconstruction
frommicrosatellite analyses ofmiracidia.47 Analyses using our
newly developed statistical tools indicated that, despite the
(minimum) number of adult worm pairs present in school-aged
children having reduced over time in response to PZQ treat-
ment, there was little or no evidence of any corresponding
reduction in parasite infection intensities, as measured by
EPG. This indicated there was a relaxation of the density-
dependent inhibition on schistosome fecundity following
treatment with PZQ among these S. mansoni populations.31
FIGURE 2. Identification of density-dependent fecundity changes after treatment with praziquantel (PZQ) as revealed by population genetic
analyses but not by standard (monitoring and evaluation) parasitological microscopy. In high worm-burden host environments, density-dependent
fecundity down regulates the per capita egg contribution of each male–female worm pair. Treatment with PZQ reduces the size of the parasite
population, relaxing density-dependent inhibition of parasite fecundity. This enables increased egg production in drug-resistant or reduced-
susceptibility parasites that survive treatment. Consequently, microscopy identifies only a limited reduction in egg output, whereas population
genetic analyses allow direct identification of the number of female worms. The combined use of microscopy and population genetic techniques
permits estimation of the egg output per female worm.
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Furthermore, it highlighted how the continued high EPG in-
fection intensity levels observed after PZQ treatment could
have, without the added value of population genetic analyses,
been erroneously otherwise interpreted as evidence of, for
instance, either lack of treatment coverage and/or reduced
drug efficacies if measured only through standard monitoring
and evaluation parasitological protocols. Nevertheless, it
must also be emphasized that where interventions, through
reductions in size of the parasite population, relax density-
dependent inhibition in parasite fecundity, as observed here,
this can also subsequently lead to increased reproduction
rates in drug-resistant or reduced-susceptibility parasites that
survive treatment.61
Our ongoing analyses of SCORE S. haematobium pop-
ulations from Zanzibar appear, however, to indicate that such
density dependence in response to PZQ/control pressures
may not be universal because there was no obvious evidence
of relaxeddensity-dependent inhibition in parasite fecundity in
relation to intervention arm. Rather, it appeared that both the
number of estimated adult worms and the estimated egg
output per female worm significantly reduced across all arms
on both islands. Although this could potentially reflect species
differences between S. haematobium and S. mansoni, con-
sistent with their contrasting mean daily egg output per adult
worm, it is important to acknowledge that the aforementioned
Tanzanian S. mansoni populations represented a true pre-
treatment baseline population,44 whereas these Zanzibar
S. haematobium populations had been subjected to many
previous treatments, over several years, with PZQ before the
start of the SCORE/ZEST program.62 Indeed, within these
ZanzibarianS. haematobium populations, there was evidence
of density dependence within individuals in relation to host
age and gender (and, hence, also infection intensity profiles),
consistent with that previously documented through pop-
ulation genetic analyses for both S. mansoni in Tanzania31,47
and S. haematobium in Mali.44 Furthermore, population ge-
netic and statistical analyses did indicate inherent differences
in schistosome fecundity levels by site across both islands,
frequently consistent with those shehias that went on to be
classed as nonresponder hotspot sites. Thus, althoughwhere
and under what conditions density dependence regulates
schistosome transmission dynamics remains complex, and
certainly further work is required in terms of its measurement
(including, despite its additional logistical challenges, in terms
of maximizing miracidial sampling over multiple time points
per host), we have demonstrated its existence and potential
for the interpretation of, and resilience within, public health
interventions. Likewise, our results to date do emphasize that
potential variability in density-dependent process must now
be incorporated into thosemathematical transmissionmodels
which are being increasingly used to inform intervention policy
and design decisions.
The challenge of interspecific hybridization. One of
the most notable results to date with the SCORE population
genetic analyses from Niger was the consistently high pro-
portions, often around 80%, of hybridized Schistosoma
combinations observed, specifically that of S. haematobium
with Schistosoma bovis hybrids, in comparison with the pure
S. haematobium originally targeted for investigation. Fur-
thermore, most of the infected Bulinus snails across all sites
were found to be transmitting the livestock schistosome
S. bovis alone, with the remainder, fromonly five villages north
of Niamey, shedding hybrids and only very few shedding
S. haematobium. Hybridization of parasites is an emerging
public health concern at the interface of infectious disease
biology and evolution. Increasing economic development,
human migration, global trade, and climate change are all
modifying the geographic distribution of existing human,
livestock, companion animal, and wildlife parasites.10 As a
result, human populations encounter new infections more
frequently, and coinfection bymultiple parasites fromdifferent
lineages or species within individual hosts can occur. When
closely related species, such as within the S. haematobium
group here, coinfect a host, introgression can result (the in-
troduction of single genes or chromosomal regions from one
species into that of another through repeated backcrossing),
and whole genome admixture can occur through hybridiza-
tion. Such hybridization can havemajor implications in light of
the current global push for humandisease control programs to
shift from controllingmorbidity to interrupting transmission.2,9
To what proportion, and where, such hybrids are ancient or
ongoing,2,9,63–65 how such introgression may alter host range
or hostmorbidity, andwhat this implies regarding our concept
of species within the Schistosoma system and beyond are
critical areas to explore in future research. The challenge of
hybridization of schistosomes for routineMDAmonitoring and
evaluation of parasitological-based diagnostics, however,
versus molecular typing diagnostics, is illustrated in Figure 3.
The challenge of PZQ resistance. Last, but by no means
least, is the role population genetic (and genomic) analyses
can play in elucidating the sustainability of any drug essential
for PC/MDA. Drug efficacy, or drug resistance, could not be
directly examined within the overall SCORE framework be-
cause of the inability to interfere with the timings of the treat-
ment schedule and ethical requirements regarding the need to
treat those found to be infected. Nevertheless, the potential
importance of drug resistance for operational research and
effective disease control, and the need to predict and/or de-
tect as it emerges, cannot be overstated. Drug resistance has
been the bane of veterinary anthelmintic treatments, and for
human schistosomiasis, this is a particularly pertinent issue,
given that PZQ is currently the only drug available for PC.
Although the genetics of anthelminthic resistance in general
are poorly understood, this is particularly true in regard to the
genetics of PZQ resistance in schistosomes. Indeed, even the
potential mechanism of action of PZQ remains uncertain.
Resistance generally arises through repeated andextensive
exposure of the parasite to the selective pressure of a che-
motherapeutic agent. Parasites that survive multiple expo-
sures to a given drug may pass on genetic variants that make
theoffspringmore resistant to thedrug. The rate and likelihood
of resistance developing is influenced by a broad range of
factors including, but not exclusive to, baseline parasite ge-
netic structure and underlying standing variation in drug tol-
erance on which selection can act, effective population size,
refugia, and gene flow in parallel to treatment frequency,
dosage, and whether single or combination drug regimens.66,67
Figure 4 demonstrates how population genetics can, never-
theless, help evaluate and contribute to the detection of po-
tential changes in drug resistance efficacy.
Given this inherent range of factors influencing the rate and
likelihood of PZQ resistance emerging, as may be predicted,
population genetic data gathered to date can be contradic-
tory, particularly in relation to the time of assessment. For
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example, S. mansoni collected 4–6 weeks after treatment in
Brazil has been reported to show reduced genetic diversity,68
with a similar reduction in S. mansoni genetic diversity
6 months after a single PZQ treatment in two schools in
Tanzania.69,70 However, genetic diversity of S. mansoni from
these same regions of Tanzania over a 5-year period of MDA
was not found to be reduced.47 Similarly, one longitudinal
study examining the genetic diversity and population struc-
ture of S. mansoni at the beginning of a national control pro-
gram in Uganda in 2003, within a highly endemic region on
Lake Victoria, found that although egg output and genetic
diversity significantly decreased immediately after drug ad-
ministration, both recovered within 6 months.67 Both these
Tanzanian47 andUgandan67 studies alsoobserved lowgenetic
FIGURE 4. Identification of potential praziquantel (PZQ)-resistant parasites as revealed by population genetic analyses but not by standard
(monitoring andevaluation) parasitologicalmicroscopy.Parasiteswith reducedsusceptibility toPZQaremore likely to survive exposure to thedrug,
increasing the frequency of reduced-susceptibility/resistant variants (PZQ-R) in subsequent generations. Standardmicroscopy identifies sustained
egg output after treatment, which may be indistinguishable from relaxation of density-dependent fecundity. Population genetic analyses can
identify changing genetic structure and ultimately quantify the frequency of PZQ-R genotypes.
FIGURE 3. Identification of infecting species/hybridized species combinations as revealed by population genetic analyses but not by standard
(monitoring and evaluation) parasitological microscopy. Hybridization and introgression can occur when closely related schistosome species
coinfect a host. In humans coinfected with different species or hybridized schistosomes, standard parasitological microscopy only provides
information on egg output and egg shape. Population genetic analyses in hatched miracidia can identify, for example, here Schistosoma hae-
matobium hybridized with livestock Schistosoma bovis and/or Schistosoma curassoni.
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differentiation between children from different schools, in-
dicative of high rates of parasite gene flow at this geographic
scale. This is likely to reduce the likelihood of local adaptation,
so even if repeated drug treatments select resistant genotypes,
these may be diluted and outcompeted by new genotypes
migrating in. These findings also suggested that resistance to
PZQmaybeunlikely toestablishor spread in thesepopulations
at the beginning of the national control program, given the
current selection of targeting school-aged children alone.69
Nevertheless, these studies on S. mansoni susceptibility to
PZQ (at least withinUganda), as recent findings have shown for
oxamniquine resistance,66 have identified standing variation in
drug efficacies and clearance rates onwhich selection can act.
This might indeed be expected to accentuate as drug pres-
sures over time increase. It is possible that evidence of such
may be apparent already within Uganda, at least, where those
populations under the longest and strongest past treatment
pressures have been associated with significant reductions in
drug efficacy.15
Therefore, even without current molecular markers of PZQ
resistance, we can demonstrate that quantifying population
structure can help predict the likelihood of genotype spread
when local populations are under selection, such as by PZQ
MDA. TheWHO recommends that efficacy be assessed either
when there is a suspicion that PZQ is not performing as
expected despite satisfactory coverage and adherence or
when the drug has been distributed by MDA for 4 years or
more.25 In practice, this guidance is seldom adopted and the
efficacy of PZQ is not monitored on a systematic basis. The
fact that some schistosomes do survive exposure to PZQ as it
is currently dosed and that PZQ is being distributed on an
unprecedented scale should be a strong stimulus to monitor
for the possible development of drug resistance on a more
routinebasis. Indeed,mathematical predictivemodels already
suggest that the increased chemotherapeutic treatment
pressures now being dispensed in SSA might allow both
parasites with drug resistance/intermediate susceptibility to
successfully invade andcoexistwith susceptible and resistant
parasite strains.71
Implications and applications of genetic studies for
Schistosoma control or elimination in SSA. Gene flow, ef-
fective population sizes, reproductive and mating systems,
host transmission and host specificity, and the standing var-
iation in terms of potential resistance alleles, to name but a
few, will all affect the epidemiology of schistosomiasis by
influencing the evolutionary potential of these parasites in
response to the control pressures imposed on them. Un-
derstanding these parameters will help predict the likelihood
of success while mitigating against the evolution and estab-
lishment of drug resistance and increase the longevity and
sustainability of interventions. When designing disease con-
trol programs, andmonitoring and evaluating their impact, it is
essential that we can accurately understand and predict par-
asite populations. Indeed, knowing the population boundaries
is required to characterize the units relevant for infection
control and the geographical scale at which control measures
must be applied. Because of their complex indirectly trans-
mitted life cycle, size, and locationwithin the (human) definitive
host, deciphering the patterns of transmission and mating/
reproductive patterns of schistosomes requires indirect meth-
ods such as population genetic analyses using tools such as
microsatellite markers.
Within those SCORE countries and treatment arms encom-
passing population genetic analyses, further insights have
been revealed that could not have been achieved by clas-
sical prevalence and intensity parasitological tools alone.
We have also observed a basic challenge to genetic studies
based on the cluster randomization design in these oper-
ational research studies. For example, with bothS.mansoni
on mainland Tanzania and S. haematobium in Niger, where
wehave seenextremely high levels of gene flow, themigration
of parasites between treatment arms and villages, and be-
tween treated and untreated people, occurs and mitigates
against definitive demarcation of treatment pressure impact.
By contrast, the potential limited gene flow of S. haematobium
on the Zanzibar islands may result in contrasting population
genetic structures between even geographically close areas,
overwhelming any potential treatment arm effects imposed.
Furthermore, there is no general consensus on how to define
biological hotspots,basedonparasitegenetics/responsiveness,
as distinct from operational hotspots, even if a broad definition
that accounts for any failure to decrease prevalence and/or in-
tensity over time is favored.72 However, population genetic
analyses on these SCORE datasets to date indicate that, with
regard to Tanzanian S. mansoni at least, persistence may relate
to localized high-transmission water contact sites, whereas in
Zanzibar, it may relate more to inherent differences in the fe-
cundity and, hence, egg output of the infecting S. haematobium
across small geographical scales, potentially independent of the
treatment arm. In regard toSCOREstudies fromNiger, themajor
factor relating to ongoing transmission sites appeared to be the
geographical variation in the occurrence of introgressed hy-
bridized schistosomes between S. haematobium with S. bovis.
Although such hybridization events in Niger may well be in-
dependent of the SCORE treatment arms, they do highlight the
issue of animal reservoirs of schistosome infection in SSA, and
the need for a One Health approach to achieve WHO control
and elimination targets.9,73
It should be noted that all the SCORE parasite samples
are archived within the Schistosomiasis collection at Natural
History Museum (SCAN) repository.74 This, coupled with the
increased availability of genome sequences and the re-
cent advances and affordability of DNA sequencing technol-
ogies, will greatly facilitate comparative studies of species/
populations from contrasting situations (such as between those
in PHS from responder sites). This will further facilitate the iden-
tification of loci of particular interest, and population genetic and
genomic studies of schistosomes may become even more
helpful in determining the impact of differential treatment regi-
mens on schistosomes. In turn, such findings will shed light on
what strategies and counterstrategies schistosomes may pos-
sess to help maintain and maximize their ongoing transmission.
Population genetic and genomic analyses of these complex and
resourceful parasites under intervention pressure should help
further elucidate fundamental principles of ecological and evo-
lutionary theory from that of host specialization, reproductive
mode, transmissiondynamics, speciation, and evenperhaps the
evolution of parasitism itself, as well as providing much needed
information for control and elimination efforts.
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